Key Highlights
● IN8bio's gamma-delta T-cell therapy INB-200 showed longer progression-free and overall survival than historical glioblastoma benchmarks in a small Phase 1 study now published in a peer-reviewed journal, adding validation to a pipeline still years from any approval decision.
● As of March 31, 2026, IN8bio reported cash of $21.9 million, down from $27.1 million at year-end 2025 but up from $11.9 million a year earlier, reflecting a December 2025 private placement.
● The clinical data remain from small, single-arm, early-phase trials compared against historical rather than randomized controls, so reported survival benefits, while promising, are not yet definitive.
● Investors should watch for further clinical updates on INB-200 as the pipeline advances toward larger controlled trials.
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biotech developing gamma-delta T-cell therapies, announced on July 9, 2026 that peer-reviewed results from its Phase 1 trial of INB-200 in newly diagnosed glioblastoma had been published in The Journal of Clinical Oncology. The publication reported that patients who received repeat dosing of the therapy alongside standard chemoradiation achieved a median progression-free survival of 16.1 months, versus an approximately 6.9-month historical benchmark for standard of care alone. The company had disclosed similar, though not identical, figures in earlier 2026 updates tied to a related, larger patient cohort, and framed the journal publication as independent validation of its DeltEx drug-resistant immunotherapy (DRI) platform. Glioblastoma remains a cancer with limited treatment options and a poor prognosis, making any signal of a meaningful survival benefit closely watched, even from small, early-stage, non-randomized data.
What happened
The Journal of Clinical Oncology publication covered the full Phase 1 trial of INB-200, a first-in-human study of 13 newly diagnosed glioblastoma patients treated with the Stupp regimen (surgical resection, chemoradiation, maintenance chemotherapy) plus one, three, or up to six doses of genetically modified, drug-resistant gamma-delta T cells. In the repeat-dose cohort, median progression-free survival was 16.1 months and median overall survival 19.5 months, versus roughly 6.9 and 14.6 months for historical standard-of-care benchmarks cited in the release. Across all 13 patients regardless of dosing schedule, median progression-free survival was 9.9 months, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity reported. Separately, on June 1, 2026, IN8bio presented updated ASCO data from a combined analysis of 17 patients across INB-200 and related INB-400, showing median overall survival exceeding 19.5 months (not yet reached) and 24-month survival of 43%, versus 13.2 months and 20% for a contemporaneously enrolled standard-of-care group; progression-free survival there was 13.0 versus 6.6 months. Chief executive William Ho said the results "validate the scientific foundation" of the DeltEx platform.
Why the development matters
For a company with no approved products and a market capitalization near $11 million, peer-reviewed clinical validation is a meaningful de-risking step, even at small scale. Publication in a major oncology journal subjects the data to external editorial scrutiny a press release does not, which can matter for future partnering talks and investor confidence in the underlying science. Investors should note, though, that the trial was small (13 to 17 patients depending on the analysis), non-randomized, and benchmarked against historical rather than concurrent, randomized controls, a design that cannot rule out patient-selection effects. IN8bio has also disclosed at least two different progression-free survival figures (16.1 months in the JCO paper's repeat-dose subgroup versus 13.0 months in the broader ASCO/INB-400 comparison), reflecting different cohorts and analysis windows rather than one static result, worth keeping in mind against headline claims of survival "doubling."
Company and product background
IN8bio's lead programs are built on its DeltEx platform, engineering gamma-delta T cells, an immune cell subset that can recognize tumors independent of traditional antigen-presentation pathways. INB-200 and the related INB-400 study modify autologous gamma-delta T cells so they can survive chemotherapy and be re-dosed repeatedly in newly diagnosed glioblastoma; both remain in Phase 1/2 development, with no FDA approval or expedited designation disclosed in the sources reviewed. The company's second program, INB-100, is an allogeneic (donor-derived) gamma-delta T-cell therapy for high-risk leukemias, used alongside stem cell transplant; dosing completion was expected in early 2026, with longer-term follow-up data anticipated later in the year. IN8bio is also advancing INB-619, a preclinical CD19-targeting T-cell engager for autoimmune and oncology use, moving into IND-enabling studies with initial animal data expected in 2026. The next disclosed milestone is further glioblastoma-program updates "later this year."
Financial position
As of March 31, 2026, IN8bio reported cash of $21.9 million, down from $27.1 million at year-end 2025 but up from $11.9 million a year earlier, reflecting a December 2025 private placement that raised an initial $20.1 million tranche (net proceeds $18.5 million) of a facility sized up to $40.2 million gross. Full-year 2025 operating expenses were $19.9 million (R&D $10.2 million, G&A $9.7 million), down from $29.6 million combined in 2024, with a full-year 2025 net loss of $19.4 million versus $30.4 million in 2024. First-quarter 2026 combined R&D/G&A expense was $5.3 million and net loss was $5.1 million. Shares outstanding were approximately 9.85 million, reflecting a one-for-thirty reverse split effected in June 2025. Management said the December financing should fund operations into the first half of 2027; the roughly $5.2 million quarterly burn against the $21.9 million balance is broadly consistent with that guidance, though it is a company estimate, and further spending or dilutive issuance under its active shelf registration could alter the actual runway.
Bull case
Bulls point to consistent survival signals for INB-200 across multiple data cuts and now independent peer review, in a disease where no major treatment advance has occurred in roughly two decades. Reduced 2025 operating expenses and an extended cash runway following the December financing give the company more time to generate data without an immediate capital need. A differentiated allogeneic leukemia program (INB-100) and an emerging T-cell engager platform (INB-619) add shots on goal beyond glioblastoma.
Risk case
Skeptics note the clinical data remain from small, single-arm, early-phase trials compared against historical rather than randomized controls, so reported survival benefits, while encouraging, are not yet statistically confirmed. The company continues to post significant losses, remains pre-revenue, and will likely need financing beyond its stated runway, risking further dilution given a market capitalization near $11 million and roughly 9.85 million shares outstanding. No program carries an FDA breakthrough, fast track, or similar designation disclosed in materials reviewed, and any randomized confirmatory trial could fail to replicate early results.
What investors should watch next
1. Additional INB-200/INB-400 glioblastoma updates the company has said to expect "later this year."
Conclusion
IN8bio's peer-reviewed INB-200 data add scientific validation to a small biotech's core glioblastoma program, and the company enters the second half of 2026 with more cash on hand than a year earlier. But the underlying trials remain small and non-randomized, funding needs persist, and no regulatory pathway to approval has been defined in the disclosures reviewed, leaving the ultimate clinical and commercial significance of the data still to be established.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...